Michael Ah-Moye FRCOG
CEO and Consultant Gynaecologist
“IVF advance fails most patients”
A trial that was reported in the Times at the prestigious American Society for Reproductive Medicine annual conference in Texas revealed that screening embryos to check that they have the correct number of chromosomes before implanting into the uterus during IVF, has no benefit in women under 38 years old. The technique is known as next generation sequencing (NGS) which is an advanced form of Pre-implantation Genetic Screening (PGS). The trial was conducted in 34 clinics in four countries including UK. When the technique was first introduced four years ago it was hailed as a giant step in improving the success rate of IVF to as high as 80%, sadly like many new techniques in IVF, it is a huge disappointment.
Michael Ah-Moye our Chief Executive at the Herts & Essex Fertility Centre says we have not introduced PGS here as there has never been any robust evidence that it has any benefit in improving the success of IVF, if anything at least nine randomised controlled studies ie robust trials, have shown that it actually lowers the success of IVF. Professor Joyce Harper who is founder member and first chairman of the European Society for Human Reproduction and Embryology.
PGS cost an average of £4000 on top of the IVF and patients have to think very carefully about using a technique with no proven benefit and which could even lower their chance of success.
Michael is a member of the British Fertility Society, the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine.
Michael’s impressive experience and expertise in Assisted Conception has resulted in the successful and safe delivery of thousands of babies and in the creation of thousands of happy new families. Widely renowned for his medical prowess, he is equally respected for his meticulous, caring and personal approach to all his patients.